1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies
    Meeting Abstract

    Giantonio, B. J.; Meropol, N. J.; Catalano, P. J.; Ng, V.; Oliver, R.; Sirzen, F.; Leonard, S.; Cassidy, J.; Benson, A. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC)
    Meeting Abstract

    Goldberg, R. M.; Köhne, C. H.; Seymour, M. T.; de Gramont, A.; Porschen, R.; Saltz, L.; Rougier, P.; Tournigand, C.; Grothey, A.; Sargent, D. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials
    Meeting Abstract

    Folprecht, G.; Seymour, M. T.; Saltz, L.; Douillard, J. Y.; Stephens, R. J.; Van Cutsem, E.; Rougier, P.; Maughan, T. S.; Köhne, C. H.; Ironotecan Meta-analysis Group
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)
    Meeting Abstract

    Duffy, A.; Capanu, M.; Abou-Alfa, G. K.; Huitzel, D.; Williams, P.; Jarnagin, W.; Fong, Y.; Kelsen, D. P.; O'Reilly, E. M.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum
    Meeting Abstract

    Chung, K. Y.; Gore, I.; Fong, L.; Venook, A.; Dorazio, P.; Healey, D.; Pavlov, D.; Saltz, L. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)
    Meeting Abstract

    Cassidy, J.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Incidence and significance of thromboembolic events (TE) in patients with gastrointestinal (GI) and non-GI malignancies on systemic cytotoxic therapy
    Meeting Abstract

    Asmis, T. R.; Templeton, M.; Trocola, R.; Pincus, N.; Randazzo, J.; Marinela, C.; Kelsen, D. P.; Shah, M. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2)
    Meeting Abstract

    Azuma, M.; Yang, D.; Carpanu, M.; Hollywood, E.; Lue-Yat, M.; Zhang, W.; Danenberg, K. D.; Danenberg, P. V.; Saltz, L.; Lenz, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Chemotherapy of liver tumors: Systemic therapy for matastatic colorectal cancer
    Book Section

    Abou-Alfa, G. K.; Saltz, L. B.
    In Blumgart, L. H.; Belghiti, J.; Jarnagin, W. R.; DeMatteo, R. P.; Chapman, W. C.; Büchler, M. W.; Hann, L. E.; D'Angelica, M. (Eds.) Surgery of the Liver, Biliary Tract, and Pancreas. 4th ed (2007)

    Fulltext@MSK | Save
  • Chemotherapy of liver tumors: Systematic therapy for hepatocellular carcinoma
    Book Section

    Abou-Alfa, G. K.; Saltz, L. B.
    In Blumgart, L. H.; Belghiti, J.; Jarnagin, W. R.; DeMatteo, R. P.; Chapman, W. C.; Büchler, M. W.; Hann, L. E.; D'Angelica, M. (Eds.) Surgery of the Liver, Biliary Tract, and Pancreas. 4th ed (2007)

    Fulltext@MSK | Save